Sort   by:  
 Page size 
UnknownComparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.
Not available
S-EPMC8291723 | biostudies-literature
UnknownTumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
Not available
S-EPMC8446913 | biostudies-literature
UnknownP08.19 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)
Not available
S-EPMC5782648 | biostudies-literature
UnknownEfficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Not available
S-EPMC5570193 | biostudies-literature
UnknownSafety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Not available
S-EPMC5961429 | biostudies-literature
UnknownEBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
Not available
S-EPMC7976507 | biostudies-literature
UnknownIdentification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria.
Not available
S-EPMC11531662 | biostudies-literature
UnknownEfficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Not available
S-EPMC10382259 | biostudies-literature
UnknownA phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Not available
S-EPMC10761073 | biostudies-literature
UnknownGlioma progression is shaped by genetic evolution and microenvironment interactions.
Not available
S-EPMC9189056 | biostudies-literature
Sort   by:  
 Page size